AstraZeneca, Ionis unveil full PhIII data for 'mega brand' ATTR drug
AstraZeneca and Ionis fleshed out a Phase III win for eplontersen Monday morning at this year’s American Academy of Neurology meeting, illustrating why the pair is so confident in its potential success.
Eplontersen all but halted patients’ disease progression after 66 weeks in a fatal neurodegenerative disease known as hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). In a composite score of polyneuropathy clinical measurements like muscle strength and blood pressure, patients taking eplontersen recorded a 0.28-point average increase from baseline compared to a 25.06-point average increase in the placebo group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.